Trinity Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2002
Net Income	-21.53	-24.02	-41.01	0.88	-6.39	-28.91	Upgrade
Depreciation & Amortization	-	1.78	2.33	2.74	3.08	4.89	Upgrade
Share-Based Compensation	-	2.07	1.76	1.1	0.79	0.76	Upgrade
Other Operating Activities	21.53	8.3	36.01	6.91	27.19	28.68	Upgrade
Operating Cash Flow	-	-11.87	-0.91	11.63	24.67	5.42	Upgrade
Operating Cash Flow Growth	-	-	-	-52.86%	355.44%	-25.07%	Upgrade
Capital Expenditures	-	-2.7	-5.98	-8.69	-10.2	-11.85	Upgrade
Acquisitions	-	28.16	0	0	0	0	Upgrade
Change in Investments	-	-0.7	0	0	0	0	Upgrade
Investing Cash Flow	-	24.76	-5.98	-8.69	-10.2	-11.85	Upgrade
Share Issuance / Repurchase	-	0	25.4	0	0	0	Upgrade
Debt Issued / Paid	-	-15.74	-37.52	-6.02	-2.72	-7.53	Upgrade
Other Financing Activities	-	-0.3	-0.2	-	-	-	Upgrade
Financing Cash Flow	-	-16.04	-12.32	-6.02	-2.72	-7.53	Upgrade
Exchange Rate Effect	-	-0.04	-0.11	0.06	0.09	0.09	Upgrade
Net Cash Flow	-	-2.84	-19.22	-1.47	10.84	-13.97	Upgrade
Free Cash Flow	-	-14.57	-6.89	2.94	14.47	-6.44	Upgrade
Free Cash Flow Growth	-	-	-	-79.70%	-	-	Upgrade
Free Cash Flow Margin	-	-25.64%	-11.01%	3.62%	14.19%	-7.12%	Upgrade
Free Cash Flow Per Share	-	-1.91	-1.65	0.70	3.46	-1.34	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).